The discovery of the methylation of the O6-methylguanin-DNA-methyltransferase (MGMT) promoter in 2008 opened up new possibilities in glioblastoma therapy [2,3,4]: hypermethylation of the MGMT promoter is associated with significantly longer survival in patients that receive an adjuvant radio-chemotherapy with temozolomide, according to the EORTC/NCIC protocol [5]. The gene discussed is MGMT; the disease is glioblastoma.